Clinical Trial Endpoints: Choosing and Measuring What Matters

Clinical trial endpoints are the specific measurements used to determine whether an intervention has produced a meaningful effect. The selection of appropriate endpoints determines whether a trial can answer its research question, whether results will be accepted by regulators, and whether patients will receive therapies that genuinely improve their lives. This article explains the types of endpoints used in clinical trials, provides a framework for selecting them, and discusses the practical considerations that researchers must address when designing studies.

Understanding Clinical Trial Endpoints

An endpoint is a defined measurement that is evaluated to assess the effect of an intervention in a clinical trial. Endpoints serve as the basis for determining whether a treatment works, how well it works, and whether its benefits outweigh its risks. The choice of endpoints shapes every aspect of trial design, including sample size, duration, statistical analysis, and interpretation of results.

Trials should be designed with consideration of the individual disease context and research question, and many different approaches may be justified depending on the circumstances. The principal components of trial design include determining a target population, establishing eligibility criteria, using stratification methods to ensure balanced control of variance across the trial, selecting adequate controls, and defining endpoints that answer the research question. The acceptability of trial designs to participants should form an integral part of protocol development, as patient and family perspectives influence recruitment, retention, and the practical feasibility of the study [7].

Primary, Secondary, and Exploratory Endpoints

Clinical trials typically categorize endpoints into three tiers based on their role in the study. This hierarchy helps researchers prioritize measurements and ensures that the most important questions are addressed with appropriate statistical rigor.

Primary Endpoints

The primary endpoint is the main measurement used to determine whether the intervention has achieved its intended effect. It is the outcome on which the trial's sample size calculation is based, and it provides the answer to the principal research question. A trial may have one primary endpoint or, in some cases, coprimary endpoints that must both show benefit for the trial to be considered successful.

The selection of a primary endpoint requires careful consideration of what constitutes a clinically meaningful effect in the specific disease context. For example, in trials for perianal fistulizing Crohn's disease, the lack of high-quality randomized controlled trials with primary endpoints specifically validated for this condition has contributed to suboptimal treatment recommendations. Analysis of the main endpoint in 10 phase III and IV trials highlighted the lack of universal definitions for clinical fistula response and remission, with most trials assessing clinical response based on physical examination that had not been formally validated. Future trials should use coprimary clinical and radiologic assessments to capture both how the patient feels and an objective measure of disease activity [8].

Secondary Endpoints

Secondary endpoints provide additional information about the intervention's effects beyond the primary question. These measurements are typically specified in advance and may include outcomes related to safety, quality of life, or other aspects of disease activity. Secondary endpoints are interpreted in the context of the primary endpoint results, and findings from secondary analyses are generally considered hypothesis-generating instead of definitive.

The interpretation of secondary endpoints requires attention to statistical considerations. When multiple secondary endpoints are tested, the risk of false-positive findings increases, and some researchers apply correction methods to account for multiple comparisons. However, the application of such corrections can create paradoxes in interpretation, as secondary analyses may be held to stricter standards than the primary endpoint itself [16].

Exploratory Endpoints

Exploratory endpoints are measurements included to generate hypotheses for future research instead of to provide answers. These endpoints may examine biological mechanisms, identify potential biomarkers, or explore effects in patient subgroups. Results from exploratory analyses should be clearly labeled as such and should not be used to make claims about treatment efficacy without confirmation in dedicated studies.

Clinical Versus Surrogate Endpoints

The distinction between clinical and surrogate endpoints is fundamental to understanding how trials are designed and interpreted.

Clinical Endpoints

Clinical endpoints measure outcomes that directly reflect how a patient feels, functions, or survives. Examples include overall survival, the occurrence of disease-related events, symptom improvement, and quality of life measures. Clinical endpoints are generally considered the most meaningful outcomes because they capture the effects that matter most to patients.

Overall survival remains the gold standard for interpreting the impact of new therapies in many disease areas. However, as outcomes have improved, it has become increasingly challenging to use overall survival as the primary endpoint if timely approval of novel agents is to be ensured. In multiple myeloma, for example, the measurement of overall survival is the gold standard for phase 3 trials, but the use of surrogate endpoints such as progression-free survival and response to treatment has contributed to approval decisions by regulatory agencies [20].

Surrogate Endpoints

Surrogate endpoints are laboratory measurements, physical signs, or other indirect measures that are intended to predict clinical benefit. A surrogate endpoint is useful when it reliably predicts the clinical outcome of interest and can be measured earlier, more easily, or with greater precision than the clinical outcome itself.

The validation of surrogate endpoints requires strong evidence that treatment effects on the surrogate correspond to treatment effects on the clinical outcome. For example, a meta-analysis of individual participant data from 66 studies with a total of 186,312 participants examined whether glomerular filtration rate decline could serve as a surrogate endpoint for kidney failure. Treatment effects on the clinical endpoint were strongly associated with treatment effects on the total slope of GFR decline, supporting the use of total slope as a primary endpoint for clinical trials of chronic kidney disease progression [22].

Similarly, a meta-analysis of albuminuria as a surrogate endpoint for kidney failure has been conducted to evaluate whether this biomarker reliably predicts clinical outcomes [18]. The validation of such surrogates requires analysis across a diverse spectrum of interventions and populations.

In vaccine research, a central goal is to characterize and validate immune correlates of protection. A correlate of protection can serve as a valid surrogate endpoint for an infectious disease clinical outcome and may qualify as a primary endpoint for vaccine authorization or approval without requiring resource-intensive phase 3 trials. However, it is challenging to persuasively validate a correlate of protection because a prognostic immune marker can fail as a reliable basis for predicting vaccine efficacy against a clinical outcome, and the statistical analysis of phase 3 trials has limited capacity to disentangle association from cause [19].

Anatomic and Biomarker Endpoints

Some disease areas rely on anatomic or biomarker endpoints that reflect disease progression. In nonexudative age-related macular degeneration, it is impractical to use change in visual acuity as a primary endpoint because by the time visual acuity has been lost, proof-of-concept early-stage clinical trials would take years to run. Surrogate endpoints are needed that reliably predict future vision loss and can be easily measured. Anatomic changes that correlate with disease progression offer the greatest promise as primary endpoints, with the growth of geographic atrophy being the most commonly used anatomic endpoint for the study of late, nonexudative disease [9].

In nonalcoholic steatohepatitis, a liver biopsy is the only generally acceptable method for diagnosis and assessment of progression toward cirrhosis. Currently accepted endpoints for conditional approval include resolution of NASH without worsening of fibrosis or improvement in fibrosis without worsening of NASH, as evaluated by standardized assessment of paired liver histology [13].

Endpoint Selection Framework

The selection of endpoints requires a systematic approach that considers the disease context, the stage of development, the intended use of the results, and the practical constraints of the trial.

Disease Context

The natural history of the disease, the availability of effective treatments, and the mechanisms of action of the investigational intervention all influence endpoint selection. In diseases with rapid progression and high mortality, clinical endpoints such as overall survival may be feasible and appropriate. In diseases with slow progression or where clinical events are rare, surrogate endpoints may be necessary to make trials feasible.

The variability of disease over time is an important consideration. In nonalcoholic fatty liver disease, the natural history is highly variable, prone to endogenous and exogenous disease modifiers, and can fluctuate over time. Consideration of the natural fluctuation of disease, the clinical implication of the chosen primary endpoint, and factors that may affect placebo response will facilitate an accurate determination of efficacy [13].

Trial Phase

The phase of development influences the type of endpoint that is appropriate. Early-phase trials typically focus on safety, tolerability, and evidence of biological activity, using endpoints that can be measured in small numbers of patients over short durations. Later-phase trials require endpoints that demonstrate clinically meaningful benefit and that will be accepted by regulators and the clinical community.

In idiopathic pulmonary fibrosis, a key element in the success of clinical trials is the choice of the best endpoints to match the design of the study. Although the results of many IPF clinical trials have been disappointing, these trials have provided valuable insights into the epidemiology and natural history of the disease and have sparked debate into the best clinical trial designs and endpoints [10].

Patient Perspectives

The voice of patients and their families should form an integral part of trial design. The acceptability of trial designs to participants affects recruitment and retention, and endpoints should reflect outcomes that patients consider meaningful [7]. Value-based trial design represents a paradigm that focuses more on symptoms and endpoints that patients care about, incorporates fewer research centers, and measures a state or consequence of disease at home or at work. Such trials measure the subjective experience of subjects in relation to other objective measurements, with endpoints suitable for individual assessment of the effect of an intervention [14].

Regulatory Considerations

Regulatory authorities provide guidance on acceptable endpoints for different disease areas and stages of development. The U.S. Food and Drug Administration has supported the use of minimal residual disease as an accelerated approval endpoint in multiple myeloma, reflecting the evolving acceptance of surrogate endpoints when they are reasonably likely to predict clinical benefit [20].

Decision Matrix for Endpoint Selection

The following table provides a framework for selecting endpoints based on disease area and trial phase. This matrix is intended to guide discussion and should be adapted to the specific context of each trial.

Practical Implementation Steps

The selection of endpoints should follow a structured process that ensures all relevant factors are considered.

Step 1: Define the Research Question

Articulate the specific question the trial is designed to answer. The research question should specify the population, the intervention, the comparator, and the outcome of interest. This formulation provides the foundation for endpoint selection.

Step 2: Review Existing Evidence

Examine the literature on the disease, the intervention, and endpoints used in similar trials. The National Center for Biotechnology Information provides access to literature resources that can inform this review [5]. PubMed, maintained by the National Library of Medicine, offers a comprehensive database of biomedical literature for identifying relevant studies and endpoint validation evidence [6].

Step 3: Identify Candidate Endpoints

Generate a list of potential endpoints based on the disease mechanism, the intervention's expected effects, and the outcomes that matter to patients. Consider both clinical and surrogate endpoints, and evaluate the evidence supporting each candidate.

Step 4: Evaluate Feasibility

Assess whether each candidate endpoint can be measured reliably, within the trial's timeframe, and with acceptable burden to participants. Consider the availability of validated measurement instruments, the need for specialized assessments, and the costs associated with data collection.

Step 5: Select Primary and Secondary Endpoints

Choose the primary endpoint that best answers the research question while being feasible to measure. Select secondary endpoints that provide additional clinically relevant information. Specify all endpoints in the protocol before the trial begins.

Step 6: Define Measurement Methods

Establish standardized procedures for measuring each endpoint, including training for assessors, quality control measures, and plans for handling missing data. The Laboratory Quality Management System Handbook from the World Health Organization provides guidance on quality management principles that apply to laboratory-based endpoint measurements [1].

Step 7: Plan Statistical Analyses

Specify the statistical methods that will be used to analyze each endpoint, including how the primary analysis will be conducted, how missing data will be handled, and how multiple comparisons will be addressed.

Records and Measurements

Accurate and complete data collection is essential for endpoint measurement. The quality of endpoint data depends on the rigor of the measurement procedures and the documentation of all relevant information.

Measurement Standards

Laboratory-based endpoints require validated analytical methods. The U.S. Food and Drug Administration's Bioanalytical Method Validation Guidance provides recommendations for the validation of bioanalytical methods used to measure drug concentrations and other laboratory parameters [4]. The Assay Guidance Manual from the National Center for Advancing Translational Sciences offers detailed information on the development and validation of assays used in drug development [3].

The Laboratory Biosafety Manual from the World Health Organization provides guidance on safe handling of biological materials, which is relevant when endpoint measurements involve processing of patient samples [2].

Data Quality

The reliability of endpoint measurements depends on the quality of the data collection process. Standardized case report forms, clear definitions of each endpoint, and training for all personnel involved in data collection help ensure consistency across sites and over time.

Documentation

Complete documentation of all endpoint measurements, including the date, time, method, and personnel involved, supports the integrity of the trial and facilitates independent verification of results.

Common Failure Patterns in Endpoint Selection

Several recurring problems can undermine the validity of clinical trials through poor endpoint selection or implementation.

Lack of Validation

Using surrogate endpoints that have not been adequately validated against clinical outcomes can lead to incorrect conclusions about treatment efficacy. A prognostic marker can fail as a reliable basis for predicting clinical outcomes, and the statistical analysis of trials has limited capacity to disentangle association from cause [19].

Inconsistent Definitions

When endpoints are not defined consistently across trials, results cannot be compared or combined. In perianal fistulizing Crohn's disease, the lack of universal definitions for clinical fistula response and remission has hindered the interpretation of trial results and the development of treatment recommendations [8].

Discordance Between Surrogate and Clinical Outcomes

Surrogate endpoints may not always predict clinical benefit. In multiple myeloma, the use of progression-free survival as a surrogate endpoint warrants careful interpretation, especially for specific subgroups of patients, and studies should be designed to account for possible discordance between progression-free survival and overall survival [20].

Insufficient Statistical Power

Trials may be underpowered to detect meaningful effects on the chosen endpoint, particularly when the endpoint is rare or the treatment effect is modest. The sample size calculation should be based on realistic estimates of the endpoint rate and the expected treatment effect.

Failure to Account for Disease Fluctuation

Diseases that fluctuate over time require endpoints and trial designs that account for this variability. In nonalcoholic fatty liver disease, the natural history can fluctuate over time, and consideration of this fluctuation is necessary for accurate determination of treatment efficacy [13].

Limitations of Endpoint Approaches

Each type of endpoint has inherent limitations that researchers must acknowledge when interpreting trial results.

Clinical Endpoint Limitations

Clinical endpoints such as overall survival require long follow-up periods and large sample sizes, particularly when event rates are low. The ongoing decrease of the incidence of hard endpoints and spiraling trial costs have created pressure to evolve the current trial paradigm [14].

Surrogate Endpoint Limitations

Surrogate endpoints are only useful when they reliably predict clinical benefit. The validation of surrogates requires substantial evidence, and even validated surrogates may not capture all aspects of treatment effect. In non-small cell lung cancer, pathologic complete response has shown a strong association with event-free survival and a moderate correlation with overall survival, but the surrogate threshold effects indicate that large treatment effects on the surrogate are needed to confidently predict non-null effects on survival outcomes [21].

Patient-Reported Outcome Limitations

Patient-reported outcomes provide valuable information about how patients feel and function, but they require careful development and validation. The selection and development of clinical outcome assessments in patient-focused drug development requires attention to measurement properties, interpretation, and the burden of data collection on participants [25].

Safety and Regulatory Context

The assessment of safety is an integral component of clinical trials, and adverse events are measured as endpoints in their own right. Safety monitoring requires systematic collection of information about adverse events, with clear definitions and reporting procedures.

The regulatory context for endpoint selection varies by jurisdiction and by disease area. Regulatory authorities provide guidance on acceptable endpoints and may offer pathways for accelerated approval based on surrogate endpoints that are reasonably likely to predict clinical benefit. The evolving acceptance of surrogate endpoints reflects the balance between the need for timely access to new therapies and the requirement for evidence of meaningful clinical benefit.

Professional Escalation Criteria

Researchers should seek additional expertise or escalate concerns when certain conditions arise during endpoint selection or trial conduct.

When to Consult Regulatory Authorities

Consult regulatory authorities early in the development process when there is uncertainty about the acceptability of a proposed endpoint, when a novel surrogate endpoint is being considered, or when the disease context creates unusual challenges for endpoint selection.

When to Seek Statistical Expertise

Seek statistical consultation when designing the trial, when planning the analysis of complex endpoints, or when interpreting results that involve multiple comparisons or surrogate validation.

When to Reconsider Endpoint Selection

Reconsider the choice of endpoints if interim data suggest that the assumptions underlying the original selection are incorrect, if measurement procedures prove unreliable, or if the trial's feasibility is compromised by the chosen endpoints.

Frequently Asked Questions

What is the difference between a primary endpoint and a secondary endpoint?

The primary endpoint is the main measurement used to determine whether the intervention has achieved its intended effect and is the basis for the sample size calculation. Secondary endpoints provide additional information about the intervention's effects and are interpreted in the context of the primary endpoint results. Secondary findings are generally considered hypothesis-generating instead of definitive.

What is a surrogate endpoint in a clinical trial?

A surrogate endpoint is a laboratory measurement, physical sign, or other indirect measure that is intended to predict clinical benefit. Surrogate endpoints are useful when they reliably predict the clinical outcome of interest and can be measured earlier, more easily, or with greater precision than the clinical outcome itself. The validation of surrogate endpoints requires strong evidence that treatment effects on the surrogate correspond to treatment effects on the clinical outcome.

Why is progression-free survival used as an endpoint in cancer trials?

Progression-free survival is used as an endpoint in cancer trials because it can be measured earlier than overall survival and may allow for more timely approval of novel agents. In multiple myeloma, progression-free survival and response to treatment have contributed to approval decisions by regulatory agencies. However, the use of progression-free survival as a surrogate endpoint warrants careful interpretation, especially for specific subgroups of patients, and studies should be designed to account for possible discordance between progression-free survival and overall survival [20].

How are adverse events measured as clinical trial endpoints?

Adverse events are systematically collected and documented throughout a clinical trial, with clear definitions and reporting procedures. Safety endpoints include the frequency, severity, and relationship of adverse events to the investigational intervention. Safety monitoring is an integral component of clinical trials, and the assessment of safety requires the same rigor as the assessment of efficacy.

What is a clinical outcome assessment?

A clinical outcome assessment is a measure that describes or reflects how a patient feels, functions, or survives. Clinical outcome assessments may be reported by the patient, by a clinician, by a caregiver, or through performance of a specific task. The selection and development of clinical outcome assessments requires attention to measurement properties, interpretation, and the burden of data collection on participants [25].

When should a trial use coprimary endpoints?

Coprimary endpoints are appropriate when a single endpoint does not fully capture the intervention's intended effect or when both a clinical and an objective measure are needed to demonstrate benefit. In perianal fistulizing Crohn's disease, future trials should use coprimary clinical and radiologic assessments to capture both how the patient feels and an objective measure of disease activity [8].

How is a surrogate endpoint validated?

A surrogate endpoint is validated by demonstrating that treatment effects on the surrogate correspond to treatment effects on the clinical outcome across multiple studies and populations. Meta-analyses of individual participant data provide strong evidence for surrogate validation. For example, treatment effects on the total slope of glomerular filtration rate decline were strongly associated with treatment effects on the clinical endpoint of kidney failure across 66 studies [22].

What happens when a trial fails to meet its primary endpoint?

When a trial fails to meet its primary endpoint, the results are interpreted in the context of the prespecified analysis plan. Secondary and exploratory analyses may provide useful information for future research, but claims of treatment efficacy cannot be made based on analyses that were not specified in advance. The failure of a trial to meet its primary endpoint does not necessarily mean the intervention is ineffective, but it does mean that the trial did not provide evidence of benefit on the chosen outcome.

Related Articles

• Multiplex Real-Time RT-PCR for Differential Diagnosis of Canine Infectious Respiratory Disease Complex (CIRDC): Panel Design, Validation, and Clinical Utility
• DNA Ladder Selection Guide: Choosing the Right Size Marker for Your Gel
• Development of an Aptamer-Based Electrochemical Biosensor for Rapid Detection of Canine Parvovirus in Clinical Samples
• CRISPR-Cas12a-Based Nucleic Acid Detection for Rapid Diagnosis of Canine Distemper Virus in Clinical Samples
• Digital Droplet PCR (ddPCR) for Absolute Quantification of Swine Enteric Coronaviruses in Fecal and Oral Fluid Samples: Analytical Sensitivity and Clinical Utility

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• PubMed. National Library of Medicine.
• Clinical trial designs and endpoints.. Handbook of clinical neurology, 2024.
• Clinical Trial Endpoints for Perianal Fistulizing Crohn's Disease.. The American journal of gastroenterology, 2026.
• Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular Degeneration.. Ophthalmology, 2016.
• IPF clinical trial design and endpoints.. Current opinion in pulmonary medicine, 2014.
• Endpoints and clinical trial design for nonalcoholic steatohepatitis.. Hepatology (Baltimore, Md.), 2011.
• Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era.. Cancer journal (Sudbury, Mass.), 2017.
• Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD.. Hepatology (Baltimore, Md.), 2019.
• The Future of Clinical Trial Design: The Transition from Hard Endpoints to Value-Based Endpoints.. Handbook of experimental pharmacology, 2019.
• Beyond the Primary Endpoint.. 2026.
• The Bonferroni Paradox: When Secondary Analyses are Held to a Stricter Standard Than the Primary Endpoint [Letter].. 2026.
• Failure of the Galleri multi-cancer detection trial to meet its primary endpoint.. 2026.
• A meta-analysis of albuminuria as a surrogate endpoint for kidney failure. Nature Medicine, 2025.
• Four Statistical Frameworks for Assessing an Immune Correlate of Protection (Surrogate Endpoint) from a Randomized, Controlled, Vaccine Efficacy Trial. Vaccine, 2024.
• Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer Journal, 2024.
• Evaluating pathological complete response as an surrogate endpoint for long-term survival in patients with non-small cell lung cancer: a systematic review and meta-analysis.. International Journal of Surgery, 2024.
• A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nature Medicine, 2023.
• Application progress of clinical outcome assessment measures in patients with gastric cancer. Chinese Journal of Gastrointestinal Surgery Zhonghua Wei Chang Wai Ke Za Zhi, 2024.
• The assessment of patient clinical outcome: Advantages, models, features of an ideal model. Indian Journal of Community Health, 2016.
• Selecting and developing clinical outcome assessments in patient-focused drug development. Chinese Journal of Evidence Based Medicine, 2024.
• The assessment of patient clinical outcome: A literature discussion. Annals of Tropical Medicine and Public Health, 2017.
• Using disablement models and clinical outcomes assessment to enable evidence-based athletic training practice, part II: Clinical outcomes assessment. Journal of Athletic Training, 2008.

This article is educational and does not replace institutional policy, professional advice, or applicable safety and regulatory requirements.